BioSpecifics Technologies Corp.

In a report released today, Hapoalim Securities commented on BioSpecifics (NASDAQ: BSTC). In the report, Hapoalim was bullish on the company. Hapoalim writes, “BioSpecifics reported 1Q11 EPS of $0.51 versus our $(0.06) estimate and the company anticipates that it will now be profitable on an...

Global Hunter is out with its report today on BioSpecifics Technologies Corp. (NASDAQ: BSTC), reiterating Buy. In a note to clients, Global Hunter writes, "Our $32 fair value estimate is based on our DCF analysis that examines free cash flow through 2016. We believe there remains significant...